FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug...
Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for...
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for...
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US...
Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) -- focused on the development of novel and...
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy...
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.